Read by QxMD icon Read


Jeff M Michalski, Jennifer Moughan, James Purdy, Walter Bosch, Deborah W Bruner, Jean-Paul Bahary, Harold Lau, Marie Duclos, Matthew Parliament, Gerard Morton, Daniel Hamstra, Michael Seider, Michael I Lock, Malti Patel, Hiram Gay, Eric Vigneault, Kathryn Winter, Howard Sandler
Importance: Optimizing radiation therapy techniques for localized prostate cancer can affect patient outcomes. Dose escalation improves biochemical control, but no prior trials were powered to detect overall survival (OS) differences. Objective: To determine whether radiation dose escalation to 79.2 Gy compared with 70.2 Gy would improve OS and other outcomes in prostate cancer. Design, Setting, and Participants: The NRG Oncology/RTOG 0126 randomized clinical trial randomized 1532 patients from 104 North American Radiation Therapy Oncology Group institutions March 2002 through August 2008...
March 15, 2018: JAMA Oncology
K P Rooney, A B Miah, S A Bhide, M T Guerrero-Urbano, M T Sharabiani, K L Newbold, L Grove, K J Harrington, C M Nutting
BACKGROUND AND PURPOSE: To determine the safety and tolerability of dose-escalation using modestly accelerated IMRT in high-risk locally advanced thyroid cancer requiring post-operative radiotherapy, and to report preliminary data on efficacy. MATERIALS AND METHODS: A sequential Phase I dose-escalation design was used. Dose level one (DL1) received 58.8 Gy/28F to the post-operative bed and 50 Gy/28F to elective nodes. DL2 received 66.6 Gy/30F to the thyroid bed, 60 Gy/30F to post-operative nodal levels and 54 Gy/30F to elective nodal levels...
March 7, 2018: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
Alessandro Magli, Eugenia Moretti, Annarita Tullio, Gianluca Giannarini, Fabrizio Tonetto, Mauro Urpis, Margherita Crespi, Claudio Foti, Agnese Prisco, Margherita Polsinelli, Gioacchino De Giorgi, Giulia Bravo, Paolo Scalchi, Marco Trovò
OBJECTIVE: The approach for treating high-risk prostate cancer still presents different unresolved issues. We report the safety and efficacy of a radiation therapy strategy based on the combination of moderate hypofractioned simultaneous integrated boost (SIB) and Image Guidance. MATERIALS AND METHODS: In this phase II trial of patients with high-risk prostate cancer, Image Guided SIB-IMRT plans (Simultaneous Intensity Modulated - Intensity Modulated Radiotherapy) were delivered between 2009 and 2012...
March 8, 2018: Prostate Cancer and Prostatic Diseases
Eleftheria Alexopoulou, Theodora Katsila, Maria Tolia, Nikolaos Tsoukalas, Michael Leontsinidis, George Kyrgias, Vasilios Kouloulias, George P Patrinos, Despoina Spyropoulou, Dimitrios Kardamakis
BACKGROUND/AIM: Radiation dermatitis is observed in 95% of breast cancer patients receiving radiotherapy. The aim of this study was to explore the correlation between protein expression in tumor cells and the risk of developing radiation dermatitis. PATIENTS AND METHODS: Breast cancer patients receiving postoperative radiotherapy were included in this study. Tumor specimens from 122 patients were examined by immunohistochemistry for the expression of Ki67, ataxia telangiectasia mutated (ATM) kinase, hypoxia-inducible factor-1-alpha (HIF-1a), inducible nitric oxide synthase (iNOS), and a-glucosidase (aGluc)...
March 2018: Anticancer Research
K Schiller, M Devecka, T Maurer, M Eiber, J Gschwend, M Schwaiger, S E Combs, G Habl
BACKGROUND: 68 Ga-PSMA-PET-imaging has proven to be a highly sensitive and specific diagnostic element for patients with prostate cancer (PC). Does the standard clinical target volume (CTV) cover the majority of68 Ga-PSMA-PET detected lymph nodes (LNs) in a primary setting? METHODS: 25 out of 159 patients with primary PC who underwent68 Ga-PSMA-PET-imaging were analyzed in the process of this study. These 25 high-risk patients had a total of 126 LNs with positive68 Ga-PSMA-ligand uptake...
March 1, 2018: Radiation Oncology
Kelly C Younge, Robin B Marsh, Dawn Owen, Huaizhi Geng, Ying Xiao, Daniel E Spratt, Joseph Foy, Krithika Suresh, Q Jackie Wu, Fang-Fang Yin, Samuel Ryu, Martha M Matuszak
PURPOSE: To use knowledge-based planning (KBP) as a method of producing high-quality, consistent, protocol-compliant treatment plans in a complex setting of spine stereotactic body radiation therapy on NRG Oncology Radiation Therapy Oncology Group (RTOG) 0631. METHODS AND MATERIALS: An internally developed KBP model was applied to an external validation cohort of 22 anonymized cases submitted under NRG Oncology RTOG 0631. The original and KBP plans were compared via their protocol compliance, target conformity and gradient index, dose to critical structures, and dose to surrounding normal tissues...
March 15, 2018: International Journal of Radiation Oncology, Biology, Physics
Charles S Mayo, Jean M Moran, Walter Bosch, Ying Xiao, Todd McNutt, Richard Popple, Jeff Michalski, Mary Feng, Lawrence B Marks, Clifton D Fuller, Ellen Yorke, Jatinder Palta, Peter E Gabriel, Andrea Molineu, Martha M Matuszak, Elizabeth Covington, Kathryn Masi, Susan L Richardson, Timothy Ritter, Tomasz Morgas, Stella Flampouri, Lakshmi Santanam, Joseph A Moore, Thomas G Purdie, Robert C Miller, Coen Hurkmans, Judy Adams, Qing-Rong Jackie Wu, Colleen J Fox, Ramon Alfredo Siochi, Norman L Brown, Wilko Verbakel, Yves Archambault, Steven J Chmura, Andre L Dekker, Don G Eagle, Thomas J Fitzgerald, Theodore Hong, Rishabh Kapoor, Beth Lansing, Shruti Jolly, Mary E Napolitano, James Percy, Mark S Rose, Salim Siddiqui, Christof Schadt, William E Simon, William L Straube, Sara T St James, Kenneth Ulin, Sue S Yom, Torunn I Yock
A substantial barrier to the single- and multi-institutional aggregation of data to supporting clinical trials, practice quality improvement efforts, and development of big data analytics resource systems is the lack of standardized nomenclatures for expressing dosimetric data. To address this issue, the American Association of Physicists in Medicine (AAPM) Task Group 263 was charged with providing nomenclature guidelines and values in radiation oncology for use in clinical trials, data-pooling initiatives, population-based studies, and routine clinical care by standardizing: (1) structure names across image processing and treatment planning system platforms; (2) nomenclature for dosimetric data (eg, dose-volume histogram [DVH]-based metrics); (3) templates for clinical trial groups and users of an initial subset of software platforms to facilitate adoption of the standards; (4) formalism for nomenclature schema, which can accommodate the addition of other structures defined in the future...
March 15, 2018: International Journal of Radiation Oncology, Biology, Physics
Ganesh Narayanasamy, Dharmin Desai, Steven Morrill, Xin Zhang, Edvaldo Galhardo, Sanjay Maraboyina, Jose Penagaricano
PURPOSE: Intermediate and low dose falloff in stereotactic body radiotherapy (SBRT) of lung tumor is known to relate to normal tissue toxicity. The purpose is two-fold: to analyze the relation between RTOG parameters (namely, R50%, D2cm) in lung SBRT plans and to explore planning methods that correlate with higher than acceptable dose to normal tissue. METHODS: RTOG recommended target dose coverage, conformity index, homogeneity index, R50% and D2cm were evaluated retrospectively in 105 lung tumor SBRT plans...
February 26, 2018: Medical Physics
Daniel A Hamstra, Kuei C Lee, Avraham Eisbruch, Prasad Sunkara, Sudhir Borgonha, Babu Phillip, Kathleen C M Campbell, Brian D Ross, Alnawaz Rehemtulla
BACKGROUND: The purpose of this study was to test if oral D-methionine (D-met) reduced mucositis during chemoradiotherapy. METHODS: We conducted a placebo-controlled double-blind randomized phase II trial of D-met (100 mg/kg p.o. b.i.d.) testing the rate of severe (grades 3-4) mucositis. RESULTS: Sixty patients were randomized. Grade 2 + oral pain was higher with placebo (79% vs 45%; P = .0165), whereas grade 2 + body odor was greater with D-met (3% vs 41%; P = ...
February 23, 2018: Head & Neck
Leonard Christopher Schmeel, David Koch, Sabina Stumpf, Christina Leitzen, Birgit Simon, Heinrich Schüller, Susanne Vornholt, Felix Schoroth, Thomas Müdder, Fred Röhner, Stephan Garbe, Frederic Carsten Schmeel, Hans Heinz Schild, Timo Martin Wilhelm-Buchstab
PURPOSE: Radiation-induced skin injury represents one of the most common side effects in breast cancer patients receiving adjuvant whole-breast radiotherapy. Numerous systemic and topical treatments have been studied in the prevention and management of radiation-induced skin injury without providing sustainable treatment strategies. While superficial barrier-forming skin products such as dressings are the standard of care in wound care management, their utilization as preventive treatment approach in radiotherapy has barely attracted attention...
February 20, 2018: Acta Oncologica
Deborah T Blumenthal, Minhee Won, Minesh P Mehta, Mark R Gilbert, Paul D Brown, Felix Bokstein, David G Brachman, Maria Werner-Wasik, Grant K Hunter, Egils Valeinis, Kirsten Hopkins, Luis Souhami, Steven P Howard, Frank S Lieberman, Dennis C Shrieve, Merideth M Wendland, Cliff G Robinson, Peixin Zhang, Benjamin W Corn
Background: We previously reported the unexpected finding of significantly improved survival for newly-diagnosed glioblastoma patients when radiation therapy (RT) was initiated later (>4 weeks post-op) compared to earlier (≤2 weeks post-op). In that analysis, data were analyzed from 2855 patients from 16 NRG Oncology/RTOG trials conducted prior to the era of concurrent temozolomide (TMZ) with RT. We now report on 1395 newly-diagnosed glioblastoma patients from two studies, treated with RT and concurrent TMZ followed by adjuvant TMZ...
February 15, 2018: Neuro-oncology
Jason Klein, Alex Ghasem, Samuel Huntley, Nathan Donaldson, Martin Keisch, Sheila Conway
BACKGROUND: High-dose-rate brachytherapy (HDR-BT) and external-beam radiation therapy (EBRT) are two modalities used in the treatment of soft tissue sarcoma. Previous work at our institution showed early complications and outcomes for patients treated with HDR-BT, EBRT, or a combination of both radiation therapy modalities. As the general indications for each of these approaches to radiation therapy differ, it is important to evaluate the use of each in an algorithmic way, reflecting how they are used in contemporary practice at sites that use these treatments...
March 2018: Clinical Orthopaedics and related Research
Jolien Robijns, Sandrine Censabella, Stefan Claes, Luc Pannekoeke, Lore Bussé, Dora Colson, Iris Kaminski, Paul Bulens, Annelies Maes, Leen Noé, Marc Brosens, An Timmermans, Ivo Lambrichts, Veerle Somers, Jeroen Mebis
OBJECTIVE: Acute radiodermatitis (RD) is a distressing and painful skin reaction that occurs in 95% of the patients undergoing radiotherapy (RT). The aim of this study was to evaluate the effectiveness of photobiomodulation therapy (PBMT) in the prevention of acute RD in breast cancer (BC) patients undergoing RT. METHODS: This study was a randomized, placebo-controlled trial including 120 BC patients that underwent an identical RT regimen post-lumpectomy. Patients were randomly assigned to the laser therapy (LT) or placebo group, with 60 patients in each group...
February 10, 2018: Lasers in Surgery and Medicine
Lode J Swinnen, Anne O'Neill, Philip H Imus, Sachin Gujar, David Schiff, Lawrence R Kleinberg, Ranjana H Advani, Erin M Dunbar, Dennis Moore, Stuart A Grossman
Background: Therapy of primary CNS lymphoma (PCNSL) has focused on multi-agent chemotherapy designed to cross the blood brain barrier. Rituximab has demonstrated activity in PCNSL. E1F05 is an ECOG-ACRIN multicenter phase 2 prospective trial of rituximab with high-dose methotrexate (HD-MTX)-based chemotherapy similar to the RTOG 93-10 regimen, omitting radiotherapy. Methods: Immunocompetent patients with newly diagnosed PCNSL received HD-MTX 3.5g/m2 with vincristine every two weeks for 5 doses; procarbazine for 7 days in weeks 1, 5, and 9; cytarabine 3g/m2/day IV for 2 days in weeks 11 and 14; a dexamethasone taper over 6 weeks; and rituximab 375mg/m2 IV infusion 3 times per week for weeks 1-4...
January 2, 2018: Oncotarget
Richard K Valicenti, Stephanie L Pugh, Edouard J Trabulsi, Oliver Sartor, Eric C Ko, Michael R Girvigian, Seth A Rosenthal, Mark E Shaves, Jeannie H Hoffman-Censits, John Schallenkamp, Howard M Sandler
PURPOSE: To investigate the utility of153 Sm lexidronam (Quadramet) in the setting of men with prostate cancer status post radical prostatectomy who develop biochemical failure with no clinical evidence of osseous metastases. PATIENTS AND METHODS: Trial NRG Oncology RTOG 0622 is a single-arm phase 2 trial that enrolled men with pT2-T4, N0-1, M0 prostate cancer status post radical prostatectomy, who meet at least 1 of these biochemical failure criteria: (1) prostate-specific antigen (PSA) > 1...
March 1, 2018: International Journal of Radiation Oncology, Biology, Physics
Ming-Hui Mao, Jie Zhang, Jian-Guo Zhang
No abstract text is available yet for this article.
January 2018: Brachytherapy
Arif N Ali, Peixin Zhang, W K Alfred Yung, Yuhchyau Chen, Benjamin Movsas, Raul C Urtasun, Christopher U Jones, Kwang N Choi, Jeff M Michalski, A Jennifer Fischbach, Arnold M Markoe, Christopher J Schultz, Marta Penas-Prado, Madhur K Garg, Alan C Hartford, Harold E Kim, Minhee Won, Walter J Curran
From 1990 to 1994, patients with newly diagnosed malignant gliomas were enrolled and randomized between hyperfractionated radiation (HFX) of 72.0 Gy in 60 fractions given twice daily and 60.0 Gy in 30 fractions given once daily. All patients received 80 mg/m2 of 1,3 bis(2 chloroethyl)-1 nitrosourea on days 1-3 q8 weeks for 1 year. Patients were stratified by age, KPS, and histology. The primary endpoint was overall survival (OS), with secondary endpoints including progression-free survival (PFS) and toxicity...
March 2018: Journal of Neuro-oncology
Yoshitaka Narita
The effectiveness of chemotherapy or chemoradiotherapy for diffuse astrocytoma (DA) has been largely unknown until recently. However, a randomized controlled study (RTOG 9802) showed that adding of procarbazine, CCNU, and vincristine (PCV) chemotherapy to fractionated radiotherapy (FRT) in patients with "high-risk" WHO grade II gliomas, including DA, has significant positive impact on both progression-free survival and overall survival. Effectiveness of temozolomide (TMZ) in cases of low-grade gliomas was also reported, and a randomized phase III trial comparing FRT alone or in combination with TMZ in cases of unresectable DA (JCOG 1303) is currently ongoing...
2018: Progress in Neurological Surgery
Zhenchao Tao, Jin Gao, Liting Qian, Yifan Huang, Yan Zhou, Liping Yang, Jian He, Jing Yang, Ru Wang, Yangyang Zhang
To investigate risk factors for acute oral mucosal reaction during head and neck squamous cell carcinoma radiotherapy.A retrospective study of patients with head and neck squamous cell carcinoma who underwent radiotherapy from November 2013 to May 2016 in Anhui Provincial Cancer Hospital was conducted. Data on the occurrence and severity of acute oral mucositis were extracted from clinical records. Based on the Radiation Therapy Oncology Group (RTOG) grading of acute radiation mucosal injury, the patients were assigned into acute reaction (grades 2-4) and minimum reaction (grades 0-1) groups...
December 2017: Medicine (Baltimore)
Pirus Ghadjar, Daniel M Aebersold, Clemens Albrecht, Dirk Böhmer, Michael Flentje, Ute Ganswindt, Stefan Höcht, Tobias Hölscher, Felix Sedlmayer, Frederik Wenz, Daniel Zips, Thomas Wiegel
AIM: Overview on the use of androgen deprivation therapy (ADT) added to salvage radiation therapy (SRT) for prostate cancer patients with biochemical recurrence after prostatectomy. METHODS: The German Society of Radiation Oncology (DEGRO) expert panel summarized available evidence published between January 2009 and May 2017, and assessed the validity of the information on outcome parameters including overall survival (OS) and treatment-related toxicity. RESULTS: Two randomized controlled trials and nine relevant retrospective analyses were identified...
January 30, 2018: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"